Dana-Farber Cancer Center Institute

Share This:

Thoracic Cancer Treatment Center
44 Binney Street
Boston, Massachusetts 02115
Phone: 888.876.8008
Fax: 617.632.4413
Email Address: Dana-FarberContactUs@dfci.harvard.edu

The Dana-Farber Cancer Center Institute has a history that dates all the way back to 1947, when the late Sidney Farber founded the Children’s Cancer Research Foundation, which provided treatment to children with cancer, while developing cancer preventatives, treatments, and cures. The program was expanded to include all patients of all ages in 1969. In 1974 the name became the Sidney Farber Cancer Center, and in 1983, because of the long-term support of the Charles A. Dana Foundation, “Dana” was added to the name.

Today, the Dana-Farber Cancer Institute’s 3,000-member staff support more than 150,000 patient visits each year. The Institute is also involved in roughly 200 clinical trials at any given time, and it is famous around the world for combining clinical expertise and research together to fight cancer and to bring novel therapies into the laboratory for clinical use. Dana-Farber Cancer Institute is a federally designated comprehensive cancer center, and the National Cancer Institute, the National Institute of Allergy and Infectious Disease, and hundreds of foundations and individuals support it.

The Dana-Farber Caner Institute houses the Thoracic Cancer Treatment Center Carole M. and Philip L. Lowe Thoracic Oncology Program (TOP). The Thoracic Oncology Program has established a multidisciplinary collaborative approach to patients with

with malignant mesothelioma, lung cancer, esophageal cancer, mediastinal and thymic tumors, and metastatic cancers to the chest. The team treats patients with all types and stages of thoracic cancer, ranging from commonly occurring lung and esophageal malignancies to unique and more aggressive cases, by not only working with the patient, but by also working with the patient’s loved ones, and referring physicians in order to improve each individual patient’s prognosis.

The multidisciplinary team, which is made up of thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, nurses, physical therapists, respiratory therapists, dieticians and nutritionists, and social workers, manages multimodality therapy, meaning a combination of surgery, chemotherapy, and radiation therapy, for each patient.

In some cases, patients may require treatments that are not yet available on the mass market, called clinical trials. Patients have the opportunity to participate in these new clinical trials, which have been developed collectively, by researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Massachusetts General Hospital and other numerous other United States medical institutions.

TOP also provides services such as second opinions, comprehensive consultation and treatment, and access to timely clinical trials and treatment, for referring physicians and their patients.